HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Urban Decay Thinks Better Of China Entry, Remains “100% Cruelty-Free”

This article was originally published in The Rose Sheet

Executive Summary

Urban Decay has opted out of launching its cosmetics line in the Chinese market for the time being, following an unfavorable reaction from its fans and customers who do not see the brand’s cruelty-free ethos as harmonious with Chinese policy requiring animal testing.

You may also be interested in...



CFI Announces Gov-Supported Program To Streamline China Entry Without Animal Testing

NGO has partnered with Shanghai-based consultancy Knudsen&Co, with the support of Chinese authorities, for a pilot program to shepherd foreign cruelty-free companies through the country’s registration process for non-special-use cosmetics without animal testing.

NARS Defends China Entry, Maintaining Support For 'Cruelty-Free World'

"It is important to bring our vision of beauty and artistry to fans in the region," says Shiseido's NARS brand on its decision to launch in China. Like others that have made the same decision, NARS now is working to manage the fallout among cruelty-free intransigents.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel